ClinicalTrials.Veeva

Menu

Pragmatic Trial of Remote TDCS and Somatosensory Training for Phantom Limb Pain with Machine Learning to Predict Treatment Response (PLP-EVEREST)

Mass General Brigham logo

Mass General Brigham

Status

Enrolling

Conditions

Phantom Limb Pain

Treatments

Other: Usual Care
Device: M1 anodal home-based tDCS
Behavioral: Somatosensory Training

Study type

Interventional

Funder types

Other

Identifiers

NCT05188183
2021P003323

Details and patient eligibility

About

The investigators have designed a pragmatic trial of home-based transcranial direct current stimulation (tDCS) for phantom limb pain (PLP), the PLP-EVEREST trial (PLP-EffectiVEness pRagmatic Stimulation Trial) to test a portable device that would reach underrepresented populations and would validate this therapy in a more pragmatic setting. Subjects will be randomized to home-based tDCS of the primary motor cortex (M1) with somatosensory training or usual care only (including their current pharmacological treatments, physical therapy, and occupational therapy). The investigators will therefore test the effectiveness of home-based tDCS and somatosensory training in a real-world, home-based setting. The Investigator will compare patients randomized to this combined strategy vs. usual care alone (subjects from this group will be offered combined treatment at the end of the trial). The investigators hypothesize that the combined strategy will be associated with a significantly larger Cohen's d effect size (at least 1) compared to the control group.

Full description

The investigators have designed a pragmatic trial of home-based tDCS for PLP, the PLP-EVEREST trial (PLP-EffectiVEness pRagmatic Stimulation Trial) to test a portable device that would reach underrepresented populations and would validate this therapy in a more pragmatic setting. Subjects will be randomized to home-based tDCS of the M1 with somatosensory training or usual care only (including their current pharmacological treatments, physical therapy, and occupational therapy). The investigators will therefore test the effectiveness of home-based tDCS and somatosensory training in a real-world, home-based setting. The investigator will compare patients randomized to this combined strategy vs. usual care alone (subjects from this group will be offered combined treatment at the end of the trial). The investigators hypothesize that the combined strategy will be associated with a significantly larger Cohen's d effect size (at least 1) compared to the control group.

The investigators will perform a pragmatic, parallel randomized clinical trial. Investigators will recruit 290 participants with upper and/or lower bilateral or unilateral limb amputation and phantom limb pain in the chronic phase. All participants will be randomized to receive 20 daily sessions (4 weeks) of active anodal M1 home-based tDCS combined with somatosensory training or usual care. The participants will participate in 23 visits over 12 weeks.

Enrollment

290 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  1. Age - older than 18 years
  2. Limb amputation
  3. Patients who experience PLP regularly (at least once a week)
  4. Pain not attributable to other causes, such as peripheral inflammation
  5. Current chronic pain as defined by an average pain of at least 4 on the numeric rating scale (NRS, 0: no pain, 10: worst imaginable pain)

Exclusion criteria

  1. Any clinically significant or unstable medical or psychiatric disorder
  2. History of substance abuse in the past 6 months (according to the DSM-V criteria for substance use disorder with six or more symptoms)
  3. Uncompensated psychiatric disorder
  4. Previous significant neurological history with current significant neurological deficits
  5. Previous neurosurgical procedure with craniectomy that would affect current distribution of tDCS
  6. Contraindications to tDCS (implanted brain medical devices)

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

290 participants in 2 patient groups

M1 anodal home-based tDCS and somatosensory training
Experimental group
Description:
Investigators will use the Soterix Medical 1X1 tDCS mini-CT stimulator device (© Soterix Medical Inc.) an home-based tDCS device used in several clinical trials with no adverse events. It sends a low-level current from the positive electrode, anode, to the negative electrode, cathode. During tDCS, low amplitude direct currents are applied via scalp electrodes and penetrate the skull to enter the brain. HB-TDCS will be combined with somatosensory training that will be performed during the self-administration of tDCS, including 20 sessions over 4 weeks.
Treatment:
Behavioral: Somatosensory Training
Device: M1 anodal home-based tDCS
Usual Care
Experimental group
Description:
Usual care includes pharmacological treatments, physical therapy, occupational therapy and/or behavioral therapy that the subject is receiving.
Treatment:
Other: Usual Care

Trial contacts and locations

1

Loading...

Central trial contact

Kevin Pacheco-Barrios, MS, MSc, MPH; Felipe Fregni, MD, PhD, MPH, MMSc

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems